Related Experiment Video
Updated: Mar 28, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
10.4K
Sarcopenia Does Not Affect Survival or Outcomes in Soft-Tissue Sarcoma.
Robert J Wilson1, Vignesh K Alamanda2, Katherine G Hartley3
1Department of Orthopaedics and Rehabilitation, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Sarcoma
|December 24, 2015
Summary
Sarcopenia, a loss of muscle mass, did not impact survival or complications in soft-tissue sarcoma (STS) patients. Further research is needed to understand sarcopenia
Area of Science:
- Oncology
- Surgical Pathology
- Geriatrics
Background:
- Sarcopenia is linked to poorer outcomes in cancer patients.
- The impact of sarcopenia on soft-tissue sarcoma (STS) prognosis is not well-defined.
Purpose of the Study:
- To investigate the association between sarcopenia and survival, wound complications, and hospital length of stay (LOS) in surgically treated STS patients.
Main Methods:
- Retrospective review of 137 STS patients.
- Sarcopenia assessed via pre-treatment CT scan measuring total psoas muscle area (TPA) adjusted for height.
- Statistical analysis using Cox proportional hazard, logistic, and linear models.
Main Results:
- Height-adjusted TPA was not an independent predictor of overall survival (p=0.746).
- Age, tumor size, and grade were independent predictors of survival.
- Sarcopenia did not predict increased LOS (p=0.66), postoperative infection (p=0.56), or other wound complications (p=0.14).
Conclusions:
- Sarcopenia does not appear to influence overall survival in STS patients.
- Sarcopenia is not associated with increased length of hospital stay or wound complications after STS surgery.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.6K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.9K
5.9K
02:07Tumor Progression
7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
02:07Tumor Progression
3.5K
3.5K
03:03mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
03:03mTOR Signaling and Cancer Progression
1.7K
1.7K